lebrikizumab · Ebglyss

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved: Atopic Dermatitis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (3)
CA
  • Ebglyss (lebrikizumab injection) is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years of age and older with a body weight of at least 40 kg, whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Ebglyss can be used with or without topical corticosteroids.
Product first approved 2024Health Canada
JP
  • Atopic dermatitis not adequately controlled by existing therapy (Ebglyss Subcutaneous Injection 250 mg; Eli Lilly Japan K.K.)
Product first approved 2024biospace.com
EU
  • Ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.
Product first approved 2023EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (27)
Atopic Dermatitis
NCT05735483 · Eli Lilly and Company
2023-03-09 – 2029-04 · Atopic Dermatitis, Eczema
What this study did
NCT07873801 · Almirall, S.A.
2026-11 – 2028-06 · Atopic Dermatitis
What this study did
NCT06526182 · Almirall, S.A.
2024-07-03 – 2027-04-25 · Dermatitis, Atopic, Eczema
What this study did
NCT05559359 · Eli Lilly and Company
2022-10-18 – 2026-12 · Atopic Dermatitis, Eczema
What this study did
NCT05916365 · Almirall, S.A.
2023-05-23 – 2026-04-23 · Atopic Dermatitis
What this study did
NCT05990725 · Almirall, S.A.
2023-11-20 – 2025-06-25 · Atopic Dermatitis, Eczema
What this study did
NCT04392154 · Eli Lilly and Company
2020-06-15 – 2025-04-22 · Atopic Dermatitis
What this study did
NCT05369403 · Eli Lilly and Company
2022-12-19 – 2025-02-05 · Atopic Dermatitis
What this study did
NCT06444165 · Eli Lilly and Company
2024-06-04 – 2024-06-10 · Atopic Dermatitis
What this study did
NCT04760314 · Eli Lilly and Company
2021-03-10 – 2023-02-01 · Dermatitis, Atopic, Dermatitis, Eczema, Skin Diseases, Skin Diseases, Genetic
What this study did
NCT04626297 · Eli Lilly and Company
2020-11-17 – 2022-09-30 · Atopic Dermatitis
What this study did
NCT04250350 · Eli Lilly and Company
2020-02-11 – 2022-06-22 · Atopic Dermatitis
What this study did
Other / comorbidity
NCT07542483 · Almirall, S.A.
2026-04-24 – 2029-02 · Nummular Eczema
What this study did
NCT06339008 · Eli Lilly and Company
2024-04-26 – 2028-10 · Perennial Allergic Rhinitis (PAR)
What this study did
NCT06338995 · Eli Lilly and Company
2024-04-29 – 2028-03 · Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
What this study did
NCT06921759 · Eli Lilly and Company
2025-04-21 – 2026-07-28 · Atopic Hand and Foot Dermatitis
What this study did
NCT01868061 · Hoffmann-La Roche
2013-07-31 – 2017-01-02 · Asthma
What this study did
NCT01867125 · Hoffmann-La Roche
2013-07-25 – 2016-12-28 · Asthma
What this study did
NCT02546869 · Hoffmann-La Roche
2015-09-29 – 2016-06-29 · Asthma
What this study did
NCT02104674 · Hoffmann-La Roche
2014-06-07 – 2016-01-22 · Asthma
What this study did
Phase 2 (13)
Atopic Dermatitis
NCT03443024 · Eli Lilly and Company
2018-01-30 – 2019-05-23 · Atopic Dermatitis
What this study did
NCT02465606 · Hoffmann-La Roche
2015-07-30 – 2016-05-30 · Atopic Dermatitis
What this study did
NCT02340234 · Hoffmann-La Roche
2015-05 – 2016-04 · Atopic Dermatitis
What this study did
Other / comorbidity
NCT07620561 · University of Maryland, Baltimore
2026-09 – 2028-03 · Prurigo Nodularis (PN)
What this study did
NCT01872689 · Hoffmann-La Roche
2013-10-13 – 2017-11-06 · Idiopathic Pulmonary Fibrosis
What this study did
NCT01987492 · Hoffmann-La Roche
2014-02-21 – 2016-12-19 · Asthma
What this study did
NCT02546700 · Hoffmann-La Roche
2015-09-17 – 2016-11-25 · Chronic Obstructive Pulmonary Disease
What this study did
NCT02099656 · Hoffmann-La Roche
2014-11-06 – 2016-10-13 · Asthma
What this study did
NCT00971035 · Genentech, Inc.
2009-11 – 2011-02 · Asthma
What this study did
NCT00930163 · Genentech, Inc.
2009-07 – 2010-09 · Asthma
What this study did
NCT00781443 · Genentech, Inc.
2008-12 – 2009-11 · Allergic Asthma
What this study did
Phase 1 (4)
Other / comorbidity
NCT06243198 · Eli Lilly and Company
2024-03-28 – 2024-09-03 · Healthy
What this study did
NCT04840901 · Eli Lilly and Company
2021-06-02 – 2022-02-11 · Healthy
What this study did
NCT01423318 · Genentech, Inc.
2011-08 – 2012-02 · Healthy Volunteer
What this study did
Phase 4 (3)
Atopic Dermatitis
NCT06906497 · Johann E Gudjonsson MD PhD
2025-07-02 – 2028-07 · Atopic Dermatitis
What this study did
NCT07856134 · Forefront Dermatology S.C
2026-11-11 – 2028-03-31 · Atopic Dermatitis
What this study did
NCT07006792 · Eli Lilly and Company
2025-06-16 – 2026-09-21 · Atopic Dermatitis
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 1 (1)
Other / comorbidity
NCT07471932 · Almirall, S.A.
2026-02-17 – 2027-05-31 · Healthy Volunteers
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 4 (1)
Atopic Dermatitis
NCT07352566 · University of California, San Francisco
2026-08-01 – 2030-06-01 · Psoriasis, Atopic Dermatitis
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Atopic Dermatitis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Lebrikizumab (Ebglyss): this drugApprovedMonoclonal antibodyIL-13Reliable signal
NCT04178967: Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16 (Baseline to Week 16): Lebrikizumab Q2W 33.2% (95% CI 27.5 to 38.9) vs Placebo 10.8% (95% CI 5.7 to 15.9)
NCT04146363: Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16 (Baseline to Week 16): Lebrikizumab Q2W 43.1% (95% CI 37.1 to 49) vs Placebo 12.7% (95% CI 7 to 18.5)
Abrocitinib (Cibinqo)ApprovedSmall moleculeJAK1Reliable signal
NCT04345367: Percentage of Participants Achieving Greater Than or Equal to (>=) 4 Points Improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4) From Baseline at Week 2 (Week 2): Abrocitinib 200 mg QD 48.2% (95% CI 43 to 53.4) vs Dupilumab 300 mg Q2W 25.5% (95% CI 21.1 to 30)
NCT03349060: Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to 2 Points Improvement From Baseline at Week 12 (Baseline, Week 12): PF-04965842 100 mg 23.7% | PF-04965842 200 mg 43.8% vs Placebo 7.9%
Crisaborole (Eucrisa)ApprovedSmall moleculePDE4Reliable signal
NCT02118766: Percentage of Participants Who Achieved Treatment Success Based on Investigator's Static Global Assessment (ISGA) at Day 29 (Day 29): AN2728 Topical Ointment, 2 Percent 32.8% vs AN2728 Topical Ointment, Vehicle 25.4%
NCT02118792: Percentage of Participants Who Achieved Success in Investigator's Static Global Assessment (ISGA) Score at Day 29 (Day 29): AN2728 Ointment, 2 Percent (%) 31.4% vs AN2728 Ointment, Vehicle 18%
Difamilast (Moizerto / Adquey)ApprovedSmall moleculePDE4Partial signal
NCT03908970: Responder Rate of Investigator's Global Assesment(IGA) of Disease Severity (At Week 4): 1% OPA-15406 38.46% (95% CI 31.36 to 45.95) vs Placebo 12.64% (95% CI 8.18 to 18.36)
NCT03911401: IGA success (score 0 or 1 with at least a 2-grade improvement) at week 4: difamilast 0.3% 44.6% and 1% 47.1% vs vehicle 18.1%; p<0.001 for each dose vs vehicle. n=83, 85, 83 (Saeki 2022, Br J Dermatol).
Dupilumab (Dupixent)ApprovedMonoclonal antibodyIL-4R-alphaWeak signal
NCT04417894: Percentage of Participants With Hand and Foot Investigator Global Assessment (IGA) 0 or 1 at Week 16 (At week 16): Dupilumab Q2W 40.3% vs Matching Placebo 16.7%
NCT03345914: Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 at Week 16 (Week 16): Dupilumab 300 mg Q4W + TCS 32.8% | Dupilumab 100 mg or 200 mg Q2W + TCS 29.5% vs Placebo + TCS 11.4%
Nemolizumab (Nemluvio)ApprovedMonoclonal antibodyIL-31 receptor AReliable signal
NCT03989349: Percentage of Participants With Investigator's Global Assessment (IGA) Success at Week 16: Intent-To-Treat (ITT) Population (Week 16): Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg 37.7% vs Initial Treatment Period (Baseline - Week 16 Predose): Placebo 26%
NCT03985943: Percentage of Participants With an Investigator's Global Assessment (IGA) Success (IGA of 0 or 1 and a More Than Equal to [>=] 2-point Reduction): Intent-To-Treat (ITT) Population (Week 16): Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg 35.6% vs Initial Treatment Period (Baseline - Week 16 Predose): Placebo 24.6%
Roflumilast (Zoryve)ApprovedSmall moleculePDE4Reliable signal
NCT06631170: Primary endpoint, Week 4 IGA (vIGA-AD) treatment-success rate: 31.9% with 0.15% roflumilast cream vs 6.7% with vehicle (P<0.0001)
NCT04773600: Achievement of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Success at Week 4 (Week 4): Roflumilast Cream 0.15% 28.9% vs Vehicle Cream 12%
Ruxolitinib (Opzelura)ApprovedSmall moleculeJAK1/2Reliable signal
NCT03745638: Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8 (Baseline to Week 8): VC Period: Ruxolitinib 0.75% Cream BID 50% (95% CI 43.7 to 56.3) | VC Period: Ruxolitinib 1.5% Cream BID 53.8% (95% CI 47.4 to 60) vs VC Period: Vehicle Cream BID 15.1% (95% CI 9.3 to 22.5)
NCT03745651: VC Period: Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8 (Baseline to Week 8): VC Period: Ruxolitinib 0.75% Cream BID 39% (95% CI 32.6 to 45.6) | VC Period: Ruxolitinib 1.5% Cream BID 51.3% (95% CI 44.6 to 58) vs VC Period: Vehicle Cream BID 7.6% (95% CI 3.5 to 14)
TapinarofApprovedSmall moleculeAryl hydrocarbon receptor, Aryl Hydrocarbon Receptor AgonistReliable signal
NCT05014568: Percent of Subjects Who Have a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of Clear or Almost Clear (0 or 1) With a Minimum 2-grade Improvement From Baseline to Week 8. Analyses Were Done Using Multiple Imputation. (Baseline to Week 8): Tapinarof Cream 45.4% vs Vehicle Cream 13.9%
NCT05032859: Percent of Subjects Who Have a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of Clear or Almost Clear (0 or 1) With a Minimum 2-grade Improvement From Baseline to Week 8. Analyses Were Done Using Multiple Imputation. (Baseline to Week 8): Tapinarof Cream 46.4% vs Vehicle Cream 18%
Tralokinumab (Adbry)ApprovedMonoclonal antibodyIL-13Reliable signal
NCT05958407: Percentage of Participants With IGA-AHE Score of 0 (Clear) or 1 (Almost Clear) (At Week 16): Tralokinumab 40% (95% CI 31.3 to 49.4) vs Placebo 10.6% (95% CI 5 to 20.9)
Upadacitinib (Rinvoq)ApprovedSmall moleculeJAK, JAK1Reliable signal
NCT03607422: EASI-75 response at week 16 (Measure Up 2): 60.1% (upadacitinib 15 mg) vs 72.9% (upadacitinib 30 mg) vs 13.3% (placebo).
NCT03569293: EASI-75 at week 16 (Measure Up 1): 70% (196/281) upadacitinib 15mg, 80% (227/285) upadacitinib 30mg, vs 16% (46/281) placebo; adjusted difference vs placebo 53.3% [46.4-60.2] and 63.4% [57.1-69.8] respectively, both p<0.0001
ADSTEMPhase 3Cell therapyautologous adipose-derived mesenchymal stem cell (AD-MSC) therapynot yet gradedNo reviewed efficacy summary in this indication
AsivatrepPhase 3Small moleculeTRPV1Reliable signal
NCT02965118: IGA success (score 0 or 1) at week 8: 36.0% asivatrep vs 12.8% vehicle (P<.001)
Baricitinib (Olumiant)Phase 3Small moleculeJAK, JAK1/2Reliable signal
NCT03334422: Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement (Placebo, 2mg and 4mg Baricitinib) (16 Weeks): 2mg Baricitinib 10.6% | 4mg Baricitinib 13.8% vs Placebo 4.5%
NCT03334396: Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement (Placebo, 2 mg, or 4 mg Baricitinib) (16 Weeks): 2 mg Baricitinib 11.4% | 4 mg Baricitinib 16.8% vs Placebo 4.8%
GS101Phase 3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
Jaktinib (Zepuping)Phase 3Small moleculeJAK1/2/3Partial signalNo reviewed efficacy summary in this indication
LW402Phase 3Small moleculeJAK1Partial signalNo reviewed efficacy summary in this indication
ManfidokimabPhase 3Monoclonal antibodyIL-4R-alphaPartial signalNo reviewed efficacy summary in this indication
PumecitinibPhase 3Small moleculeJAK1/2not yet gradedNo reviewed efficacy summary in this indication
QL2108Phase 3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
QLM3003Phase 3Small moleculeJAKPartial signalNo reviewed efficacy summary in this indication
RademikibartPhase 3Monoclonal antibodyIL-4R-alphaPartial signal
NCT05017480: vIGA 0/1 with a reduction of 2 points or more at week 16: rademikibart 300 mg Q2W 29.0% vs placebo 5.9%, P<0.001 (SEASIDE CHINA, Br J Dermatol 2026).
RezpegaldesleukinPhase 3Protein / enzyme therapeuticIL-2 mutein (Treg-selective)not yet gradedNo reviewed efficacy summary in this indication
SHR-1819Phase 3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
Soficitinib (ICP-332)Phase 3Small moleculeTYK2/JAK1not yet gradedNo reviewed efficacy summary in this indication
SSGJ-611Phase 3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
StapokibartPhase 3Monoclonal antibodyIL-4R-alphaReliable signal
NCT06277765: EASI-75 at week 18: 73.9% (88/119) stapokibart vs 43% (26/60) placebo; difference 30.5 percentage points (95% CI 15.3-44.3; P<0.001)
NCT05265923: EASI-75 response at week 16: 66.9% stapokibart vs 25.8% placebo (significantly higher)
TelikibartPhase 3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
TilrekimigPhase 3Multispecific antibodyIL-4/IL-13/TSLPnot yet gradedNo reviewed efficacy summary in this indication
VC005Phase 3Small moleculeJAK1, JAK1not yet gradedNo reviewed efficacy summary in this indication
ZemprocitinibPhase 3Small moleculeJAK1Reliable signal
NCT06277245: EASI-75 at Week 16: +38.1 percentage points (12 mg) and +46.4 percentage points (24 mg) vs placebo (p<0.0001); IGA 0/1 response: +30.3 percentage points (12 mg) and +31.0 percentage points (24 mg) vs placebo (p<0.0001)
AfimkibartPhase 2Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
AK139Phase 2Multispecific antibodyIL-4 receptor alpha / ST2not yet gradedNo reviewed efficacy summary in this indication
BarzolvolimabPhase 2Monoclonal antibodyKITnot yet gradedNo reviewed efficacy summary in this indication
BempikibartPhase 2Monoclonal antibodyIL-7 receptor alphanot yet gradedNo reviewed efficacy summary in this indication
BFB759Phase 2Monoclonal antibodyIL-1RAPnot yet gradedNo reviewed efficacy summary in this indication
BosakitugPhase 2Monoclonal antibodyTSLPWeak signal
NCT05932654: Proportion of Patients Achieving at Least 75% Reduction in Eczema Area and Severity Index [EASI] at Week 26 (Week 26): 300 mg 94.1% (95% CI 71.3 to 99.9)
CamoteskimabPhase 2Monoclonal antibodyIL-18Partial signalNo reviewed efficacy summary in this indication
CM512Phase 2Multispecific antibodyTSLP + IL-13Weak signalFeatured results are safety only in this race
CMS-D001Phase 2Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
ENV-294Phase 2Small molecule—Weak signalFeatured results are safety only in this race
EVO101Phase 2Small moleculeIRAK4Partial signal
NCT05579899: Percent Change in Eczema Area and Severity Index (EASI) From Baseline to Week 8 (8 weeks): EVO101 Cream -43.5% (Standard Deviation 60.85) vs Vehicle Cream -62% (Standard Deviation 38.78) missed
EVO301Phase 2Protein / enzyme therapeuticIL-18Partial signal
NCT06723405: Placebo-adjusted improvement in EASI at Week 12: 33% (95% CI -50, -17; p<0.01)
FB825Phase 2Monoclonal antibodyCεmX domain of membrane-bound IgE (mIgE)Weak signalNo reviewed efficacy summary in this indication
FelcorekibartPhase 2Monoclonal antibodyTSLPnot yet gradedNo reviewed efficacy summary in this indication
GalvokimigPhase 2Multispecific antibodyIL-13, IL-17A, IL-17FPartial signalFeatured results are safety only in this race
GHZ339Phase 2Biologic (subtype unspecified)—not yet gradedNo reviewed efficacy summary in this indication
GIA632Phase 2Monoclonal antibodyIL-15not yet gradedNo reviewed efficacy summary in this indication
HSK44459Phase 2Small moleculePDE4Bnot yet gradedNo reviewed efficacy summary in this indication
HY209gelPhase 2Small moleculeGPCR19 / GPBAR1 (TGR5, bile acid receptor)Partial signalFeatured results are safety only in this race
IN-115314Phase 2Small moleculeJAK1not yet gradedNo reviewed efficacy summary in this indication
JNJ-95597528Phase 2Multispecific antibodyTSLP + IL-13not yet gradedNo reviewed efficacy summary in this indication
JYP0061Phase 2Small moleculeJAK1not yet gradedNo reviewed efficacy summary in this indication
KT-621Phase 2Small moleculeSTAT6Weak signalFeatured results are safety only in this race
LepzacitinibPhase 2Small moleculeJAK1/JAK3not yet gradedNo reviewed efficacy summary in this indication
LNK01004Phase 2Small moleculePan-JAKPartial signalFeatured results are safety only in this race
LT-002-158Phase 2Small moleculeIRAK4not yet gradedNo reviewed efficacy summary in this indication
LunsekimigPhase 2Antibody-derived scaffoldTSLP + IL-13not yet gradedNo reviewed efficacy summary in this indication
LutikizumabPhase 2Multispecific antibodyIL-1α/IL-1β (dual)not yet gradedNo reviewed efficacy summary in this indication
ModzatinibPhase 2Small moleculeITK and JAK3not yet gradedNo reviewed efficacy summary in this indication
MosedipimodPhase 2Small moleculeNF-kB / CCL26 pathwaynot yet gradedNo reviewed efficacy summary in this indication
Nitrosomonas Eutropha (B244)Phase 2Microbiome therapeuticlive biotherapeutic (topical ammonia-oxidizing bacterium, AOBiome/B244)Reliable signal
NCT04490109: Mean Change in Worst Itch Numeric Rating Scale (WI-NRS) (Baseline to Day 28): B244 O.D. 5.0 -2.8 score on a scale (Standard Error 0.184) | B244 O.D. 20.0 -2.8 score on a scale (Standard Error 0.184) vs Vehicle -2.1 score on a scale (Standard Error 0.18)
ZumilokibartPhase 2Monoclonal antibodyIL-13not yet gradedNo reviewed efficacy summary in this indication
REGN20423Phase 1Monoclonal antibodyIL-13not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 63 furthest-along competitors are listed; 49 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(8 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Ebglyss (lebrikizumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (6)
April 2027 (1)
Phase 3Atopic DermatitisActive not recruiting
Est. primary completion 2027-04-25 · NCT06526182 · CT.gov ↗
What to watch
May 2027 (1)
Phase 3Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)Recruiting
Est. primary completion 2027-05 · NCT06338995 · CT.gov ↗
What to watch
July 2027 (1)
Phase 4Atopic DermatitisActive not recruiting
Est. primary completion 2027-07 · NCT06906497 · CT.gov ↗
What to watch
August 2027 (1)
Phase 4Atopic DermatitisNot yet recruiting
Est. primary completion 2027-08-31 · NCT07856134 · CT.gov ↗
What to watch
December 2027 (2)
Phase 2Prurigo Nodularis (PN)Not yet recruiting
Est. primary completion 2027-12 · NCT07620561 · CT.gov ↗
What to watch
Phase 3Atopic DermatitisEnrolling by invitation
Est. primary completion 2027-12 · NCT05735483 · CT.gov ↗
What to watch
2028 (2)
February 2028 (1)
Phase 3Atopic DermatitisNot yet recruiting
Est. primary completion 2028-02 · NCT07873801 · CT.gov ↗
What to watch
August 2028 (1)
Phase 3Nummular EczemaRecruiting
Est. primary completion 2028-08 · NCT07542483 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

9 June 2026ApprovalFDA approves EBGLYSS once-every-eight-weeks maintenance dosing
US, FDA · Source ↗